Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
22 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Amura Holdings Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Amura Holdings Ltd. - Product Pipeline Review - 2014', provides an overview of the Amura Holdings Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Amura Holdings Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Amura Holdings Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Amura Holdings Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Amura Holdings Ltd.'s pipeline products Reasons to buy - Evaluate Amura Holdings Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Amura Holdings Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Amura Holdings Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Amura Holdings Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amura Holdings Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Amura Holdings Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Amura Holdings Ltd. Snapshot 4 Amura Holdings Ltd. Overview 4 Key Information 4 Key Facts 4 Amura Holdings Ltd. - Research and Development Overview 5 Key Therapeutic Areas 5 Amura Holdings Ltd. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Amura Holdings Ltd. - Pipeline Products Glance 9 Amura Holdings Ltd. - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Amura Holdings Ltd. - Drug Profiles 10 AM-112 10 Product Description 10 Mechanism of Action 10 R&D Progress 10 AM-3701 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 AM-3840 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 AM-3876 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Small Molecules To Inhibit Cathepsin For Malaria 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 Amura Holdings Ltd. - Pipeline Analysis 15 Amura Holdings Ltd. - Pipeline Products by Target 15 Amura Holdings Ltd. - Pipeline Products by Route of Administration 16 Amura Holdings Ltd. - Pipeline Products by Molecule Type 17 Amura Holdings Ltd. - Pipeline Products by Mechanism of Action 18 Amura Holdings Ltd. - Dormant Projects 19 Amura Holdings Ltd. - Locations And Subsidiaries 20 Head Office 20 Other Locations & Subsidiaries 20 Appendix 21 Methodology 21 Coverage 21 Secondary Research 21 Primary Research 21 Expert Panel Validation 21 Contact Us 22 Disclaimer 22
List of Tables Amura Holdings Ltd., Key Information 4 Amura Holdings Ltd., Key Facts 4 Amura Holdings Ltd. - Pipeline by Indication, 2014 6 Amura Holdings Ltd. - Pipeline by Stage of Development, 2014 7 Amura Holdings Ltd. - Monotherapy Products in Pipeline, 2014 8 Amura Holdings Ltd. - Preclinical, 2014 9 Amura Holdings Ltd. - Pipeline by Target, 2014 15 Amura Holdings Ltd. - Pipeline by Route of Administration, 2014 16 Amura Holdings Ltd. - Pipeline by Molecule Type, 2014 17 Amura Holdings Ltd. - Pipeline Products by Mechanism of Action, 2014 18 Amura Holdings Ltd. - Dormant Developmental Projects,2014 19 Amura Holdings Ltd., Other Locations 20 Amura Holdings Ltd., Subsidiaries 20
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.